News

GlaxoSmithKline, or GSK, and Stiefel Laboratories have signed an agreement to create a new specialist dermatology business. Under the terms of the agreement GSK will acquire the total

Medarex, a biopharmaceutical company, has reported encouraging preliminary data from an ongoing Phase I clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin’s lymphoma that demonstrated

Merck Serono, a division of German drug maker Merck KGaA, has launched Kuvan, an oral therapeutic indicated for the treatment of hyperphenylalaninaemia due to phenylketonuria or tetrahydrobiopterin deficiency,

Impax Pharmaceuticals, the brand products division of Impax Laboratories, has started a Phase III trial of IPX066 in Parkinson’s disease or PD patients based on encouraging interim data

US-based PerkinElmer has launched a new series of AlphaLISA No Wash immunoassay kits to help enable advanced biomarker research in multiple key disease states, including angiogenesis, inflammation and

French pharmaceutical group Sanofi-Aventis has announced an increase of capital investment in the amount of $90m to extend its current manufacturing facility located at the Beijing Economic and

Tolarex, a Hadasit Bio Holdings portfolio company, has received approval from the Ministry of Health of Israel to begin a Phase I/IIa clinical trial of its treatment for

SpePharm, a Dutch specialty pharmaceutical company, has introduced two new products, MuGard and Xerotin, aimed at relieving some of the most debilitating side effects experienced by cancer patients,

The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client